|
John Villiger is an independent director and investor. John co-founded The Medicines Company in 1996, and was Senior Vice President of Development until Febuary 2006. This business is NASDAQ listed with market capitalization of US$1.25 billion. The Medicines Company has a significant marketed product (Angiomax) with project sales of approximately $220 million in 2006, two other products in late stage clinical development (Cangrelor and Clevidipine), and around 300 employees.
Previously, John held various positions in product development at Roche from 1986 to 1996 in New Zealand and Switzerland, including International Project Director from 1991 to 1995 and Head of Global Project Management from 1995 to 1996. As Head of Global Project Management, he oversaw the development of Roche's pharmaceutical portfolio, with management responsibility for over 50 development programs and development teams in Switzerland, the UK, USA and Japan. John has a PhD in pharmacology from the University of Otago. | 